Stimatix GI, a developer of stomal management solutions, has received CE mark approval for its AOS-C2000 colostomy device.
The AOS-C2000 is designed to provide voluntary bowel evacuation and improve the quality of life of people suffering with a stoma.
Stimatix GI CEO David Hanuka said, "Obtaining the CE Mark, on schedule, along with the FDA registration completed in April this year, is an additional significant step on the path to setting a new standard in stoma care, and enhancing the quality of life for individuals with colostomies."
In addition to AOS-C2000, Stimatix GI is developing AOS-C1000 as part of its colostomy product line that provides voluntary bowel evacuation for people with a stoma.
Stimatix GI, a portfolio company of The Trendlines Group’s Misgav Venture Accelerator, Pontifax Venture Capital Fund and Lazarus Israel Opportunities Fund, is involved in developing low-profile solutions for colostomy management.